DelAQUA is an early stage company developing a novel polymer platform and late stage preclinical products to provide unprecedented drug solubilization capacity and bioactivity for a wide range of hydrophobic drugs. Our technology uses a non-PEG, stealth, hyper-loaded polymeric micelle approach that dramatically enhances the solubility and stability of drugs and drug candidates by 10,000-100,000x, thereby enhancing their efficacy and safety and widening the therapeutic window.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):